Inflammatory breast cancer treated with surgery, chemotherapy and allogeneic tumor cell/BCG immunotherapy

C. Wiseman, J. M. Jessup, T. L. Smith, Evan M Hersh, J. Bowen, G. Blumenshein

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Thirteen consecutive patients with inflammatory breast cancer were treated with a regimen consisting of cyclic chemotherapy, extended simple mastectomy, and immunotherapy utilizing irradiated allogeneic breast cancer cells admixed with BCG. When surgery was performed after two or more cycles of 5-U, doxorubicin hydrochloride, and cyclophosphamide, there was complete eradication of detectable tumor in three of 11 operative specimens. Two patients had surgery prior to our evaluation and four had prior chemotherapy. Chest wall radiation was initiated after 8-10+ months of chemotherapy at the doxorubicin cardiotoxicity limits. Seven untreated patients, all premenopausal, were compared to our previous series which employed either irradiation after several courses of chemotherapy or irradiation alone. The current series had two relapses (eight months, 25 months) at a median follow-up time of 21 months (range, 8-26 months). In the previous chemoradiotherapy trial, all nine premenopausal patients had relapsed within 25 months, with a median disease free interval of 17 months. In the trial using radiotherapy alone, all ten patients had relapsed by 19 months (median disease free interval, nine months). The present regimen appears to improve control of the disease and further investigation of both surgery and immunotherapy intercalated with cyclic chemotherapy appears warranted in this disease.

Original languageEnglish (US)
Pages (from-to)1266-1271
Number of pages6
JournalCancer
Volume49
Issue number6
StatePublished - 1982
Externally publishedYes

Fingerprint

Inflammatory Breast Neoplasms
Mycobacterium bovis
Immunotherapy
Drug Therapy
Neoplasms
Doxorubicin
Simple Mastectomy
Thoracic Wall
Chemoradiotherapy
Cyclophosphamide
Radiotherapy
Radiation
Breast Neoplasms
Recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Wiseman, C., Jessup, J. M., Smith, T. L., Hersh, E. M., Bowen, J., & Blumenshein, G. (1982). Inflammatory breast cancer treated with surgery, chemotherapy and allogeneic tumor cell/BCG immunotherapy. Cancer, 49(6), 1266-1271.

Inflammatory breast cancer treated with surgery, chemotherapy and allogeneic tumor cell/BCG immunotherapy. / Wiseman, C.; Jessup, J. M.; Smith, T. L.; Hersh, Evan M; Bowen, J.; Blumenshein, G.

In: Cancer, Vol. 49, No. 6, 1982, p. 1266-1271.

Research output: Contribution to journalArticle

Wiseman, C, Jessup, JM, Smith, TL, Hersh, EM, Bowen, J & Blumenshein, G 1982, 'Inflammatory breast cancer treated with surgery, chemotherapy and allogeneic tumor cell/BCG immunotherapy', Cancer, vol. 49, no. 6, pp. 1266-1271.
Wiseman C, Jessup JM, Smith TL, Hersh EM, Bowen J, Blumenshein G. Inflammatory breast cancer treated with surgery, chemotherapy and allogeneic tumor cell/BCG immunotherapy. Cancer. 1982;49(6):1266-1271.
Wiseman, C. ; Jessup, J. M. ; Smith, T. L. ; Hersh, Evan M ; Bowen, J. ; Blumenshein, G. / Inflammatory breast cancer treated with surgery, chemotherapy and allogeneic tumor cell/BCG immunotherapy. In: Cancer. 1982 ; Vol. 49, No. 6. pp. 1266-1271.
@article{f959a85c7d5e4283a6db1010ef7fb1ee,
title = "Inflammatory breast cancer treated with surgery, chemotherapy and allogeneic tumor cell/BCG immunotherapy",
abstract = "Thirteen consecutive patients with inflammatory breast cancer were treated with a regimen consisting of cyclic chemotherapy, extended simple mastectomy, and immunotherapy utilizing irradiated allogeneic breast cancer cells admixed with BCG. When surgery was performed after two or more cycles of 5-U, doxorubicin hydrochloride, and cyclophosphamide, there was complete eradication of detectable tumor in three of 11 operative specimens. Two patients had surgery prior to our evaluation and four had prior chemotherapy. Chest wall radiation was initiated after 8-10+ months of chemotherapy at the doxorubicin cardiotoxicity limits. Seven untreated patients, all premenopausal, were compared to our previous series which employed either irradiation after several courses of chemotherapy or irradiation alone. The current series had two relapses (eight months, 25 months) at a median follow-up time of 21 months (range, 8-26 months). In the previous chemoradiotherapy trial, all nine premenopausal patients had relapsed within 25 months, with a median disease free interval of 17 months. In the trial using radiotherapy alone, all ten patients had relapsed by 19 months (median disease free interval, nine months). The present regimen appears to improve control of the disease and further investigation of both surgery and immunotherapy intercalated with cyclic chemotherapy appears warranted in this disease.",
author = "C. Wiseman and Jessup, {J. M.} and Smith, {T. L.} and Hersh, {Evan M} and J. Bowen and G. Blumenshein",
year = "1982",
language = "English (US)",
volume = "49",
pages = "1266--1271",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Inflammatory breast cancer treated with surgery, chemotherapy and allogeneic tumor cell/BCG immunotherapy

AU - Wiseman, C.

AU - Jessup, J. M.

AU - Smith, T. L.

AU - Hersh, Evan M

AU - Bowen, J.

AU - Blumenshein, G.

PY - 1982

Y1 - 1982

N2 - Thirteen consecutive patients with inflammatory breast cancer were treated with a regimen consisting of cyclic chemotherapy, extended simple mastectomy, and immunotherapy utilizing irradiated allogeneic breast cancer cells admixed with BCG. When surgery was performed after two or more cycles of 5-U, doxorubicin hydrochloride, and cyclophosphamide, there was complete eradication of detectable tumor in three of 11 operative specimens. Two patients had surgery prior to our evaluation and four had prior chemotherapy. Chest wall radiation was initiated after 8-10+ months of chemotherapy at the doxorubicin cardiotoxicity limits. Seven untreated patients, all premenopausal, were compared to our previous series which employed either irradiation after several courses of chemotherapy or irradiation alone. The current series had two relapses (eight months, 25 months) at a median follow-up time of 21 months (range, 8-26 months). In the previous chemoradiotherapy trial, all nine premenopausal patients had relapsed within 25 months, with a median disease free interval of 17 months. In the trial using radiotherapy alone, all ten patients had relapsed by 19 months (median disease free interval, nine months). The present regimen appears to improve control of the disease and further investigation of both surgery and immunotherapy intercalated with cyclic chemotherapy appears warranted in this disease.

AB - Thirteen consecutive patients with inflammatory breast cancer were treated with a regimen consisting of cyclic chemotherapy, extended simple mastectomy, and immunotherapy utilizing irradiated allogeneic breast cancer cells admixed with BCG. When surgery was performed after two or more cycles of 5-U, doxorubicin hydrochloride, and cyclophosphamide, there was complete eradication of detectable tumor in three of 11 operative specimens. Two patients had surgery prior to our evaluation and four had prior chemotherapy. Chest wall radiation was initiated after 8-10+ months of chemotherapy at the doxorubicin cardiotoxicity limits. Seven untreated patients, all premenopausal, were compared to our previous series which employed either irradiation after several courses of chemotherapy or irradiation alone. The current series had two relapses (eight months, 25 months) at a median follow-up time of 21 months (range, 8-26 months). In the previous chemoradiotherapy trial, all nine premenopausal patients had relapsed within 25 months, with a median disease free interval of 17 months. In the trial using radiotherapy alone, all ten patients had relapsed by 19 months (median disease free interval, nine months). The present regimen appears to improve control of the disease and further investigation of both surgery and immunotherapy intercalated with cyclic chemotherapy appears warranted in this disease.

UR - http://www.scopus.com/inward/record.url?scp=0020072372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020072372&partnerID=8YFLogxK

M3 - Article

VL - 49

SP - 1266

EP - 1271

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -